Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
Lai, K.W., Romero, F.A., Tsui, V., Beresini, M.H., de Leon Boenig, G., Bronner, S.M., Chen, K., Chen, Z., Choo, E.F., Crawford, T.D., Cyr, P., Kaufman, S., Li, Y., Liao, J., Liu, W., Ly, J., Murray, J., Shen, W., Wai, J., Wang, F., Zhu, C., Zhu, X., Magnuson, S.(2018) Bioorg Med Chem Lett 28: 15-23
- PubMed: 29169673 
- DOI: https://doi.org/10.1016/j.bmcl.2017.11.025
- Primary Citation of Related Structures:  
6ALC - PubMed Abstract: 
A novel, potent, and orally bioavailable inhibitor of the bromodomain of CBP, compound 35 (GNE-207), has been identified through SAR investigations focused on optimizing al bicyclic heteroarene to replace the aniline present in the published GNE-272 series. Compound 35 has excellent CBP potency (CBP IC 50 = 1 nM, MYC EC 50 = 18 nM), a selectively index of >2500-fold against BRD4(1), and exhibits a good pharmacokinetic profile.
Organizational Affiliation: 
WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China.